background An interankle systolic blood pressure (SBP) difference has been associated with overall and cardiovascular mortality. We investigated whether an association existed between this difference and ankle-brachial index (ABI), brachial-ankle pulse wave velocity (baPWV), and echocardiographic parameters.
Ankle blood pressure (BP) is usually measured in conjunction with arm BP; the ankle-brachial index (ABI) is then calculated. Current technology allows simultaneous BP measurement in 4 limbs, 1 which might provide a comprehensive evaluation of BP differences between 4 limbs, such as ABI and the interarm and interankle BP differences. The importance of a BP difference between arms is recognized because it has been associated with subclavian stenosis, peripheral vascular disease, preexisting coronary artery disease, left ventricular hypertrophy (LVH), and increased cardiovascular and all-cause mortality. [2] [3] [4] [5] [6] A recent study showed that the normal upper limit for interankle SBP difference was 16.7 mm Hg in the general population. 7 Sheng et al. found that an interankle SBP difference (≥ 15 mm Hg or ≥10 mm Hg) predicted mortality in the elderly, and this relation remained significant after exclusion of patients with ABI < 0.9. 8 In addition, a recent study by our team reported that a difference in SBP ≥ 15 mm Hg or in diastolic BP (DBP) ≥ 10 mm Hg between ankles was associated with atherosclerosis and increased risk for cardiovascular and overall mortality in hemodialysis patients. Furthermore, this difference remained an independent predictor for overall and cardiovascular mortality after further adjustment for atherosclerosis. 9 Hence, some mechanisms other than atherosclerosis might be responsible for the correlation between an interankle BP difference and adverse outcomes.
Accordingly, using simultaneous 4-limb BP measurement, our aim was to compare peripheral vascular disease and echocardiographic parameters between patients with and without an interankle SBP difference ≥ 15 mm Hg and to identify the independent factors associated with this difference.
METHODS

Study patients and design
Study patients from a group of patients who arranged for echocardiographic examinations at Kaohsiung Municipal Hsiao-Kang Hospital from April 2010 to October 2011 were prospectively included in the study. Patients with significant aortic or mitral valve diseases, atrial fibrillation, or inadequate image visualization were excluded. We did not include all patients consecutively because ABI, brachial-ankle pulse wave velocity (baPWV), and BPs must be measured within 10 min after completion of an echocardiographic examination. Finally, 1,059 patients (mean age 60.8 ± 13.7 years; 603 (56.9%) males) were included.
Evaluation of cardiac structure and function
An experienced cardiologist certified by the Taiwan Society of Echocardiography and using a VIVID 7 (General Electric Medical Systems, Horten, Norway) performed the echocardiographic examination, with the participant respiring quietly in the left decubitus position. The cardiologist was blinded to the other data. Two-dimensional and 2-dimensionally guided M-mode images were recorded from the standardized views. The Doppler sample volume was placed at the tips of the mitral leaflets to obtain the left ventricular inflow waveforms from the apical 4-chamber view. All sample volumes were positioned with ultrasonic beam alignment to flow. Pulsed tissue Doppler imaging was obtained with the sample volume placed at the lateral corner of the mitral annulus from the apical 4-chamber view. The wall filter settings were adjusted to exclude high-frequency signals, and the gain was minimized. The echocardiographic measurements included left atrial (LA) diameter, left ventricular internal diameter in diastole (LVIDd), left ventricular posterior wall thickness in diastole (LVPWTd), interventricular septal wall thickness in diastole (IVSTd), E-wave deceleration time, transmitral E-wave velocity (E), transmitral A-wave velocity, and early diastolic mitral annulus velocity (Ea). Left ventricular systolic function was assessed by left ventricular ejection fraction (LVEF). Left ventricular mass was calculated using the Devereux-modified method: left ventricular mass = 1.04 × [(IVSTd + LVIDd + LVPWTd) 3 
Assessment of ABI and baPWV
The values of ABI and baPWV were measured using an ABI-form device (VP1000; Colin Co. Ltd., Komaki, Japan), which automatically and simultaneously measures 4-limb BPs using an oscillometric method. 1 The ABI was calculated based on the ratio of the ankle SBP divided by the higher SBP of the arms. After obtaining bilateral ABI values, the lower value was used for later analysis. To measure baPWV, pulse waves obtained from the brachial and tibial arteries were recorded simultaneously and the transmission time, defined as the time interval between the initial increase in brachial and tibial waveforms, was determined. The transmission distance from the arm to each ankle was calculated according to body height. The baPWV value was automatically computed as the transmission distance divided by the transmission time. After obtaining bilateral baPWV values, the higher value was used as representative for each patient. The ABI and baPWV measurements were taken once for each patient. The validation of this automatic device and its reproducibility have been previously described. 1
Assessment of BP
To prevent overestimation and observer bias, interankle difference of BP is assessed with simultaneously BP measurement at both ankles with 1 or 2 automated devices. 12 In our study, the bilateral ankle BPs were measured simultaneously and automatically using the ABI-form device once after a rest period of at least 5 min in the supine position. The SBP and DBP were measured using an appropriate cuff, and the average of SBP and DBP of bilateral ankles was used for statistical analysis.
Collection of demographic, medical, and laboratory data
Demographic and medical data, including age, gender, smoking history, and comorbid conditions, were obtained from medical records or patient interviews. Study patients were defined as having diabetes mellitus if the fasting blood glucose level was ≥ 126 mg/dL or hypoglycemic agents were used to control blood glucose levels. Similarly, study patients were considered as having hypertension if the SBP was ≥ 140 mm Hg or DBP ≥ 90 mm Hg or antihypertensive drugs were prescribed. Coronary artery disease was defined as a history of typical angina with positive stress test, angiographically documented coronary artery disease, old myocardial infarction, or having undergone coronary artery bypass surgery or angioplasty. The body mass index was calculated as the ratio of weight, in kilograms, divided by the square of height, in meters. Laboratory data were measured from fasting blood samples using an autoanalyzer (Roche Diagnostics GmbH, D-68298 Mannheim COBAS Integra 400). Serum creatinine was measured using the compensated Jaffé (kinetic alkaline picrate) method in a Roche/Integra 400 analyzer (Roche Diagnostics, Mannheim, Germany) using a calibrator traceable to isotope dilution mass spectrometry. 13 The value of estimated glomerular filtration rate (eGFR) was calculated using the 4-variable equation from the Modification of Diet in Renal Disease study. 14 Blood samples were obtained within 1 month of enrollment. In addition, information regarding patient medication use during the study period, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blocker, calcium channel blocker, and diuretics, was obtained from medical records.
Statistical analysis
Statistical analysis was performed using SPSS 15.0 for Windows (SPSS Inc., Chicago, IL). Data are expressed as percentages, mean ± standard deviation, or median (25th-75th percentile) for interankle and interarm SBP differences and triglyceride. The differences between groups were checked by Chi-square test for categorical variables or by independent t test for continuous variables. Multiple logistic regression analysis was used to identify the factors associated with an interankle SBP difference ≥ 10, 15, or 20 mm Hg. Significant variables in univariate analysis were selected as covariates for multivariate analysis. A significant improvement in model prediction was studied by calculating the improvement in −2-log likelihood or adjusted R square values. A difference was considered significant if P < 0.05.
RESULTS
The mean age of the 1,059 patients was 60.8 ± 13.7 years. The prevalence of interankle SBP difference ≥ 15 mm Hg was 13.7%. The differences between patients with and without an interankle SBP difference ≥ 15 mm Hg are presented in Table 1 . Compared with patients with an interankle SBP difference < 15 mm Hg, those with an interankle SBP difference ≥ 15 mm Hg were found to be older and to have higher prevalence of diabetes and coronary artery disease, higher mean arterial pressure, higher prevalence of ABI < 0.9 (P < 0.001), higher baPWV (P < 0.001), and lower eGFR. In addition, patients with an interankle SBP difference ≥ 15 mm Hg had a higher LA diameter (P < 0.001), higher LVMI (P < 0.001), higher prevalence of LVH (P = 0.010), lower LVEF (P = 0.026), lower Ea (P < 0.001), higher E/Ea (P < 0.001), and higher E-wave deceleration time (P = 0.001). Table 2 presents the determinants of an interankle SBP difference ≥ 15 mm Hg in our study patients. In the univariate regression analysis, an interankle SBP difference ≥ 15 mm Hg was found to be significantly associated with older age, a history of diabetes and coronary artery disease, high mean arterial pressure, ABI < 0.9, high baPWV, low eGFR, high LA diameter, high LVMI, low LVEF, low Ea, high E/Ea, and high E-wave deceleration time. In the multivariate forward analysis, diabetes, ABI < 0.9 (odds ratio (OR), 11.710; 95% confidence interval (CI), 6.245-21.958; P < 0.001), high baPWV (per 10 cm/s; OR, 1.008; 95% CI, 1.004-1.012; P < 0.001), and increased LVMI (OR, 1.006; 95% CI, 1.002-1.010; P = 0.004) were independently associated with an interankle SBP difference ≥ 15 mm Hg.
In addition, we performed analyses using 10 mm Hg or 20 mm Hg as a cutoff value of interankle SBP difference. Multivariate analysis showed the association of ABI < 0.9 (both P < 0.001) and high baPWV (P ≤ 0.001) with an interankle SBP difference ≥ 10 mm Hg (n = 321, 30.3%) or ≥ 20 mm Hg (n = 85, 8.0%) still existed, but the association of LVMI with an interankle SBP difference ≥ 10 mm Hg (P = 0.132) or ≥ 20 mm Hg (P = 0.841) did not reach statistical significance.
The addition of an interankle SBP difference ≥ 15 mm Hg to a basic model (age, sex, diabetes, hypertension, coronary artery disease, mean arterial pressure, eGFR, and interarm SBP difference ≥ 10 mm Hg) significantly improved the value in predicting ABI < 0.9 (difference in −2 log likelihood value: 35.649; P < 0.001) and in predicting increased LVMI (difference in adjusted R square: 0.004; P = 0.036).
Since ABI < 0.9 has been reported to be associated with LVH, [15] [16] [17] we performed a subgroup analysis after excluding 59 patients with ABI < 0.9 (Table 3) . After the multivariate analysis (covariates included age, a history of diabetes, mean arterial pressure, body mass index, eGFR, LA diameter, LVMI, Ea, E/Ea, and E-wave deceleration time), we found that diabetes, high mean arterial pressure, increased LVMI (OR, 1.006; 95% CI, 1.002-1.011; P = 0.008), and high E-wave deceleration time remained independently associated with an interankle SBP difference ≥ 15 mm Hg.
Since an interarm SBP difference ≥ 10 mm Hg has recently been associated with LVH, 6 we also performed a subgroup analysis after excluding 77 patients with an interarm SBP difference ≥ 10 mm Hg (Table 4) . After the multivariate analysis (covariates included age, history of diabetes and coronary artery disease, mean arterial pressure, eGFR, LA diameter, LVMI, LVEF, Ea, E/Ea, and E-wave deceleration time), we found a similar result, that is, the relation between increased LVMI and an interankle SBP difference ≥ 15 mm Hg still existed (OR, 1.004; 95% CI, 1.000-1.009; P = 0.045).
DISCUSSION
In our study, using a simultaneous measurement technique, we found that ABI < 0.9, high baPWV, and increased LVMI were independently associated with an interankle SBP difference ≥ 15 mm Hg. However, an interankle SBP difference ≥ 10 mm Hg or ≥ 20 mm Hg only correlated with ABI < 0.9 and high baPWV, but not with increased LVMI in the multivariate analysis. In addition, the relation between an interankle SBP difference ≥ 15 mm Hg and increased LVMI existed even after patients with ABI < 0.9 and patients with an interarm SBP difference ≥ 10 mm Hg were excluded. Furthermore, the addition of an interankle SBP difference ≥ 15 mm Hg to a model of clinical features could significantly improve the value in predicting ABI < 0.9 and increased LVMI.
A clinical device, the ABI-form (Colin VP1000, Komaki, Japan), has been developed to automatically and simultaneously measure BPs in both arms and ankles and to record pulse waves of the brachial and posterior tibial arteries using an automated oscillometric method. Using this device, the values of ABI and baPWV, which are good markers for peripheral vascular disease, can be obtained easily. 1, 18 Previous studies reported that interankle SBP difference predicted overall and cardiovascular mortality even after exclusion of patients with ABI < 0.9. 8, 9 Unequal limb atherosclerosis might contribute to an interankle BP difference, giving the interankle BP difference prognostic value for overall and cardiovascular survival as atherosclerosis worsened. 19, 20 Our study revealed that ABI < 0.9 and high baPWV were significantly associated with an interankle SBP difference ≥ 15 mm Hg. In addition, one important finding of our study was that there was a significant association between increased LVMI and the interankle SBP difference. Hence, an interankle SBP difference ≥ 15 mm Hg might have the potential to become a useful parameter in predicting the presence of peripheral vascular disease and increased LVMI.
Previous studies demonstrated that the ABI value in the LVH group was significantly lower than that in the non-LVH group and was independently and reversely associated with LVMI. 21, 22 These results suggested that low ABI might be related to LVH. In our study, we performed the subgroup analysis after excluding patients with ABI < 0.9 and found that the significant correlation between an interankle SBP difference and LVMI still existed. Hence, even in patients with ABI ≥ 0.9, calculation of interankle BP difference may be helpful in identifying patients with increased LVMI.
Sheng et al. 8 compared the predictive power of interarm and interankle SBP differences for adverse cardiovascular outcomes. An interankle SBP difference predicted overall and cardiovascular mortality, but an interarm SBP difference Abbreviations: A, transmitral A-wave velocity; ABI, ankle-brachial index; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; baPWV, brachial-ankle pulse wave velocity; DBP, diastolic blood pressure; E, transmitral E-wave velocity; Ea, early diastolic mitral annulus velocity; eGFR, estimated glomerular filtration rate; LA, left atrial; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; SBP, systolic blood pressure.
only predicted overall, but not cardiovascular, mortality. Also, after exclusion of patients with ABI < 0.9, an interankle SBP difference still significantly predicted mortality, whereas an interarm SBP difference did not, suggesting interankle SBP difference might provide an additional prognostic benefit over interarm SBP difference. In our study, after excluding patients with an interarm SBP difference ≥ 10 mm Hg, an interankle SBP difference ≥ 15 mm Hg was still significantly associated with increased LVMI. Therefore, even in patients with interarm SBP difference < 10 mm Hg, the interankle SBP difference was useful in identifying groups at high risk of increased LVMI.
There were several limitations to our study. First, because the study was cross-sectional, the causal relationship could not be confirmed. Future prospective studies are needed to address this issue. Second, the majority of patients were treated chronically with antihypertensive medications. For ethical reasons, we did not withdraw these medications. Hence, we could not exclude the influence of antihypertensive agents on our findings. Third, because the beat-to-beat variation of BPs, ABI, and baPWV during atrial fibrillation is high, we excluded patients with atrial fibrillation. Hence, our results could not be applied in this patient population. Finally, because the study participants were already being evaluated for heart disease using echocardiography, our study was susceptible to selection bias, making findings potentially less generalized.
In conclusion, our results demonstrated that ABI < 0.9, high baPWV, and increased LVMI were significantly correlated with an interankle SBP difference ≥ 15 mm Hg. In addition, interankle SBP difference could offer an extra benefit in identifying patients with ABI < 0.9 and increased LVMI beyond conventional clinical features. Hence, calculation of interankle SBP difference during routine BP measurement may provide additional information for identifying patients with peripheral vascular disease and increased LVMI.
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